Table 2. Unadjusted Rates and Adjusted Percentage Point Differences of Molecular Testing and Targeted Therapy Use in Patients with Metastatic NSCLC and Colorectal Cancera.
| Characteristic | NSCLC | Colorectal cancer | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any molecular testing | Multigene panels | Targeted therapy use | Any molecular testing | Multigene panels | Targeted therapy use | |||||||
| Unadjusted rate, % | Adjusted difference (95% CI), percentage point | Unadjusted rate, % | Adjusted difference (95% CI), percentage point | Unadjusted rate, % | Adjusted difference (95% CI), percentage point | Unadjusted rate, % | Adjusted difference (95% CI), percentage point | Unadjusted rate, % | Adjusted difference (95% CI), percentage point | Unadjusted rate, % | Adjusted difference (95% CI), percentage point | |
| Practice type | ||||||||||||
| NCI-designated center | 78.9 | [Reference] | 13.2 | [Reference] | 16.6 | [Reference] | 56.9 | [Reference] | 5.5 | [Reference] | 5.0 | [Reference] |
| Other academic center | 78.3 | −1.3 (−3.7 to 1.1) | 7.2 | −4.7 (−6.8 to −2.6) | 9.1 | −4.8 (−6.4 to −3.2) | 57.2 | 0.8 (−3.2 to 4.9) | 4.8 | −0.9 (−2.4 to 0.6) | 6.1 | 1.2 (−0.4 to 2.7) |
| Other hospital-owned | 79.3 | −0.4 (−2.0 to 1.2) | 8.3 | −4.7 (−6.2 to −3.2) | 8.0 | −5.4 (−6.4 to −4.3) | 54.4 | −3.8 (−6.4 to −1.2) | 4.4 | −1.3 (−2.4 to −0.3) | 5.0 | −0.05 (−1.0 to 0.9) |
| Large independent | 80.0 | −0.01 (−1.7 to 1.7) | 7.5 | −5.0 (−6.5 to −3.6) | 7.4 | −6.4 (−7.5 to −5.2) | 54.9 | −3.3 (−6.1 to −0.4) | 4.2 | −1.8 (−2.7 to −0.8) | 4.7 | −0.3 (−1.4 to 0.9) |
| Small independent | 78.0 | −1.4 (−3.3 to 0.5) | 6.0 | −5.2 (−6.7 to −3.8) | 9.5 | −6.2 (−7.6 to −4.8) | 46.2 | −12.2 (−15.3 to −9.1) | 2.5 | −2.7 (−3.7 to −1.6) | 3.8 | −1.2 (−2.6 to 0.1) |
| Race and ethnicity | ||||||||||||
| White, non-Hispanic | 80.2 | [Reference] | 8.3 | [Reference] | 7.4 | [Reference] | 54.7 | [Reference] | 4.2 | [Reference] | 4.6 | [Reference] |
| Asian | 75.5 | −1.2 (−3.0 to 0.5) | 8.7 | −0.3 (−1.5 to 0.9) | 46.6 | 34.7 (33.2 to 36.1) | 45.3 | −5.6 (−8.9 to −2.2) | 3.1 | −0.6 (−2.0 to 0.7) | 4.5 | −0.4 (−2.2 to 1.3) |
| Black | 74.6 | −2.7 (−3.7 to −1.8) | 6.3 | −0.6 (−1.2 to 0.0) | 7.5 | 1.0 (0.1 to 1.9) | 51.0 | −1.9 (−3.8 to −0.1) | 4.3 | 0.2 (−0.6 to 0.9) | 5.2 | 0.2 (−0.9 to 1.2) |
| Hispanic | 73.6 | −2.0 (−4.6 to 0.5) | 5.7 | −1.7 (−3.4 to 0.0) | 20.8 | 11.9 (9.8 to 14.1) | 44.6 | −4.7 (−8.7 to −0.7) | 4.1 | 0.6 (−1.0 to 2.2) | 4.8 | −0.5 (−2.6 to 1.6) |
| Otherb | 73.5 | −3.5 (−4.8 to −2.1) | 9.0 | −0.1 (−1.0 to 0.8) | 22.6 | 14.0 (12.7 to 15.3) | 51.4 | −0.9 (−3.3 to 1.5) | 3.8 | −0.5 (−1.4 to 0.5) | 6.5 | 0.7 (−0.7 to 2.1) |
| Dual eligible | ||||||||||||
| No | 80.3 | [Reference] | 8.4 | [Reference] | 8.3 | [Reference] | 54.9 | [Reference] | 4.4 | [Reference] | 4.7 | [Reference] |
| Yes | 74.6 | −3.9 (−4.6 to −3.2) | 6.8 | −1.1 (−1.6 to −0.7) | 12.6 | 1.1 (0.5 to 1.8) | 49.1 | −4.2 (−5.6 to −2.8) | 3.1 | −1.1 (−1.6 to −0.5) | 4.7 | −0.3 (−1.1 to 0.4) |
Abbreviations: NCI, National Cancer Institute; NSCLC, non–small cell lung cancer.
a
Models were also adjusted for year and quarter, age, sex, urban or rural residence, area median income, area education level, Charlson Comorbidity score. Colorectal models were also adjusted for tumor location.
b
Includes Pacific Islander, American Indian or Alaska Native, other, and unknown.